Trevi Therapeutics Inc (TRVI)
2.865
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
2.865
0.00 (0.00%)
After-Hours: 20:00
Trevi Therapeutics Enterprise Value: 154.34M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 154.34M |
| November 12, 2024 | 165.10M |
| November 11, 2024 | 170.48M |
| November 08, 2024 | 158.19M |
| November 07, 2024 | 157.42M |
| November 06, 2024 | 172.79M |
| November 05, 2024 | 166.64M |
| November 04, 2024 | 168.18M |
| November 01, 2024 | 165.87M |
| October 31, 2024 | 160.88M |
| October 30, 2024 | 165.40M |
| October 29, 2024 | 166.91M |
| October 28, 2024 | 174.45M |
| October 25, 2024 | 169.92M |
| October 24, 2024 | 169.17M |
| October 23, 2024 | 176.72M |
| October 22, 2024 | 178.22M |
| October 21, 2024 | 187.28M |
| October 18, 2024 | 169.92M |
| October 17, 2024 | 169.92M |
| October 16, 2024 | 175.96M |
| October 15, 2024 | 174.45M |
| October 14, 2024 | 174.45M |
| October 11, 2024 | 169.92M |
| October 10, 2024 | 160.87M |
| Date | Value |
|---|---|
| October 09, 2024 | 160.12M |
| October 08, 2024 | 172.19M |
| October 07, 2024 | 151.82M |
| October 04, 2024 | 162.38M |
| October 03, 2024 | 162.38M |
| October 02, 2024 | 175.21M |
| October 01, 2024 | 169.17M |
| September 30, 2024 | 186.52M |
| September 27, 2024 | 172.24M |
| September 26, 2024 | 159.17M |
| September 25, 2024 | 154.09M |
| September 24, 2024 | 160.62M |
| September 23, 2024 | 170.06M |
| September 20, 2024 | 180.22M |
| September 19, 2024 | 184.58M |
| September 18, 2024 | 178.04M |
| September 17, 2024 | 172.24M |
| September 16, 2024 | 185.30M |
| September 13, 2024 | 175.14M |
| September 12, 2024 | 170.06M |
| September 11, 2024 | 170.06M |
| September 10, 2024 | 159.17M |
| September 09, 2024 | 156.99M |
| September 06, 2024 | 144.65M |
| September 05, 2024 | 155.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.82M
Minimum
Mar 30 2020
187.28M
Maximum
Oct 21 2024
43.91M
Average
25.89M
Median
Feb 19 2021
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
| Oragenics Inc | 2.142M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.24M |
| Total Expenses (Quarterly) | 14.09M |
| EPS Diluted (Quarterly) | -0.13 |
| Earnings Yield | -15.36% |